tiprankstipranks
Advertisement
Advertisement

CADL Stock Latest News

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
The FlyCandel Therapeutics initiated with an Overweight at Cantor Fitzgerald
4d ago
CADL
Candel Therapeutics price target raised to $26 from $22 at Citi
PremiumThe Fly
Candel Therapeutics price target raised to $26 from $22 at Citi
1M ago
CADL
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
PremiumRatings
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
1M ago
CADL
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
PremiumThe Fly
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
1M ago
CADL
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
PremiumRatings
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
1M ago
CADL
Candel Therapeutics price target lowered to $22 from $24 at Citi
PremiumThe FlyCandel Therapeutics price target lowered to $22 from $24 at Citi
1M ago
CADL
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
Premium
Company Announcements
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
1M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
1M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
PremiumRatings
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
1M ago
CADL
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
PremiumThe Fly
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
1M ago
CADL
Candel Therapeutics sees cash runway into 1Q28
PremiumThe Fly
Candel Therapeutics sees cash runway into 1Q28
1M ago
CADL
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
PremiumCompany Announcements
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
2M ago
8K
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe FlyCandel Therapeutics 18.3M share Spot Secondary priced at $5.45
2M ago
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
Premium
The Fly
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
2M ago
CADL
Candel Therapeutics announces $100M royalty funding agreement
Premium
The Fly
Candel Therapeutics announces $100M royalty funding agreement
2M ago
CADL
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
PremiumCompany Announcements
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
2M ago
8K
CADL
Candel Therapeutics announces $100M common stock offering
PremiumThe Fly
Candel Therapeutics announces $100M common stock offering
2M ago
CADL
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
PremiumCompany Announcements
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
3M ago
CADL
Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
PremiumRatings
Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
5M ago
CADL
Candel Therapeutics: Strategic Advancements and Regulatory Progress Support Buy Rating
PremiumRatingsCandel Therapeutics: Strategic Advancements and Regulatory Progress Support Buy Rating
5M ago
CADL
Optimistic Buy Rating for Candel Therapeutics Driven by Promising Pipeline and Strategic Milestones
Premium
Ratings
Optimistic Buy Rating for Candel Therapeutics Driven by Promising Pipeline and Strategic Milestones
5M ago
CADL
Candel Therapeutics: Promising Developments Amidst Regulatory and Market Challenges
Premium
Ratings
Candel Therapeutics: Promising Developments Amidst Regulatory and Market Challenges
5M ago
CADL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >